公开(公告)号：US06933355B2

公开(公告)日：2005-08-23

申请号：US10850600

申请日：2004-05-20

申请人： Oliver Brümmer ,  Gary M. Diamond ,  Christopher Goh ,  Anne M. LaPointe ,  Margarete K. Leclerc ,  James Longmire ,  James A. W. Shoemaker

发明人： Oliver Brümmer ,  Gary M. Diamond ,  Christopher Goh ,  Anne M. LaPointe ,  Margarete K. Leclerc ,  James Longmire ,  James A. W. Shoemaker

IPC分类号： C07D249/06 ,  C07F7/00 ,  C08F4/06 ,  C08F4/642 ,  C08F4/659 ,  C08F210/02 ,  C08F4/44 ,  C07D227/02

CPC分类号： C08F210/02 ,  C07D249/06 ,  C07F7/00 ,  C07F7/003 ,  C08F4/65908 ,  C08F4/65912 ,  C08F4/659 ,  C08F4/64 ,  C08F212/08 ,  C08F2500/03

摘要： Metal-ligand complexes that are useful as precursors to catalysts for the polymerization of olefins are provided. Certain of the catalysts are particularly effective at polymerizing ethylene and styrene into copolymers having novel properties, including a low molecular weight and close comparison between vinyl and methyl end groups.

摘要翻译： 提供了可用作烯烃聚合催化剂前体的金属 - 配体络合物。 某些催化剂特别有效地将乙烯和苯乙烯聚合成具有新特性的共聚物，包括低分子量和乙烯基和甲基端基之间的紧密比较。

公开(公告)号：US4889934A

公开(公告)日：1989-12-26

申请号：US147407

申请日：1988-01-26

申请人： Takeo Kawabata ,  Masahiko Miyashita ,  Akira Taisha

发明人： Takeo Kawabata ,  Masahiko Miyashita ,  Akira Taisha

IPC分类号： H01L51/42 ,  C07C255/23 ,  C07C255/31 ,  C07C255/45 ,  C07D213/20 ,  C07D215/10 ,  C07D217/10 ,  C07D227/02 ,  C07D233/54 ,  C07D233/58 ,  C08K5/34 ,  C08K5/3412 ,  C08K5/3432 ,  C09D5/24 ,  C09D5/25 ,  C09D11/00 ,  C09D11/52 ,  H01B1/12 ,  H01G9/028

CPC分类号： C07D213/20 ,  C07C255/00 ,  C07D215/10 ,  C07D217/10 ,  C07D233/64

摘要： Novel organic mixed complexes are provided which have the general formulaD.sup.+.[A.TCNQ]wherein D.sup.+ is an N-alkylonium cation derived from a nitrogen-containing hetercyclic compound (D) selected from the group consisting of pyridines, guinolines, isoquinolines and imidazoles and [A.TCNQ] is an anion radical derived from a 2,5-bis[(alkoxycarbonyl)-ethyl]-7,7,8,8-tetracyanoquinodimethane (A) of the formula ##STR1## in which R is an alkyl group containing 1-10 carbon atoms, and 7,7,8,8-tetracyanoquinodimethane (TCNQ).

摘要翻译： 提供了具有通式D +的新型有机混合络合物。[A.TCNQ]其中D +是衍生自选自吡啶，鸟嘌呤，异喹啉和咪唑的含氮杂环化合物（D）的N-烷基铵阳离子 和[A.TCNQ]是衍生自式“IMAGE”的2,5-双[（烷氧基羰基） - 乙基] -7,7,8,8-四氰基醌二甲烷（A）的阴离子基团，其中R是烷基 含有1-10个碳原子的基团和7,7,8,8-四氰基醌二甲烷（TCNQ）。

公开(公告)号：US11339124B2

公开(公告)日：2022-05-24

申请号：US16967871

申请日：2019-02-05

申请人： VIB VZW ,  Universiteit Antwerpen ,  Universiteit Gent

发明人： Peter Vandenabeele ,  Tom Vanden Berghe ,  Koen Augustyns ,  Sam Hofmans ,  Pieter Van Der Veken ,  Lars Devisscher

IPC分类号： C07C311/39 ,  C07D227/02 ,  C07D295/027 ,  C07D221/00 ,  C07D241/04 ,  C07D227/04

摘要： The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.

公开(公告)号：US10711313B2

公开(公告)日：2020-07-14

申请号：US15944725

申请日：2018-04-03

申请人： GUIZHOU MEDICAL UNIVERSITY ,  MATERNAL AND CHILD HEALTH HOSPITAL OF GUIYANG CITY ,  GUIZHOU ENTRY-EXIT INSPECTION AND QUARANTINE BUREAU

发明人： Wenfeng Yu ,  Shi Zhou ,  Zhi Huang ,  Bi Wang ,  Rui Gao ,  Dai Wei Zhao ,  Hai Zhuang ,  Ya Ling Liang

IPC分类号： C12Q1/68 ,  C07D227/02 ,  C12Q1/6886 ,  C12Q1/686 ,  C12Q1/6869

摘要： A kit for determining ctDNA concentration and a method for determining ctDNA concentration is disclosed, wherein the method comprising dissolving extracted ctDNA in Tris-HCl buffer with pH>7.0 and adding into the buffer 2,7-bis(1-methyl-4-vinylpyridine)-9-ethylcarbazole iodised salt as a molecular probe, calculating the concentration of ctDNA in the solution by measuring the Fluorescence intensity of the solution. It has extremely high sensitivity in the determination of 0 μg/ml˜50 μg/ml ctDNA solution.

公开(公告)号：US20050123533A1

公开(公告)日：2005-06-09

申请号：US10699966

申请日：2003-11-03

申请人： John Kenten ,  Reid Borstel ,  Jan Casadei ,  Balreddy Kamireddy ,  Mark Martin ,  Richard Massey ,  Andrew Napper ,  David Simpson ,  Rodger Smith ,  Richard Titmas ,  Richard Williams

发明人： John Kenten ,  Reid Borstel ,  Jan Casadei ,  Balreddy Kamireddy ,  Mark Martin ,  Richard Massey ,  Andrew Napper ,  David Simpson ,  Rodger Smith ,  Richard Titmas ,  Richard Williams

IPC分类号： A61K31/195 ,  A61K31/425 ,  A61K31/505 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61K31/7042 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K39/385 ,  A61K39/395 ,  A61K47/48 ,  A61P31/12 ,  A61P43/00 ,  C07C311/19 ,  C07D227/02 ,  C07D233/64 ,  C07D233/88 ,  C07D405/04 ,  C07D417/12 ,  C07D417/14 ,  C07F9/24 ,  C07F9/26 ,  C07F9/40 ,  C07F9/6509 ,  C07F9/6571 ,  C07F9/6574 ,  C07H15/252 ,  C07H19/04 ,  C07H19/067 ,  C07H19/09 ,  C07H19/10 ,  C07H19/11 ,  C07K16/46 ,  C12N15/09 ,  C12P21/08 ,  C12R1/92 ,  G01N33/50 ,  G01N33/53 ,  C07H15/24 ,  C07K16/18

CPC分类号： G01N33/5011 ,  C07C311/19 ,  C07F9/2408 ,  C07F9/2458 ,  C07F9/4006 ,  C07F9/4075 ,  C07F9/650952 ,  C07F9/657181 ,  C07H15/252 ,  C07H19/04 ,  C07K16/468 ,  G01N33/5008 ,  G01N33/5014 ,  G01N33/5088 ,  G01N33/5094 ,  G01N2500/00

摘要： Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents.

摘要翻译： 披露和要求的是由催化蛋白如酶和催化抗体活化的前药。 本发明包括这些前药以及半抗原以引发催化抗体以活化前药。 前药可用作细胞毒性化学治疗剂; 例如作为抗肿瘤剂。

公开(公告)号：US20190300961A1

公开(公告)日：2019-10-03

申请号：US15944725

申请日：2018-04-03

申请人： GUIZHOU MEDICAL UNIVERSITY ,  MATERNAL AND CHILD HEALTH HOSPITAL OF GUIYANG CITY ,  GUIZHOU ENTRY-EXIT INSPECTION AND QUARANTINE BUREAU

发明人： WENFENG YU ,  SHI ZHOU ,  ZHI HUANG ,  BI WANG ,  RUI GAO ,  DAI WEI ZHAO ,  HAI ZHUANG ,  YA LING LIANG

IPC分类号： C12Q1/6886 ,  C12Q1/6869 ,  C12Q1/686 ,  C07D227/02

摘要： A kit for determining ctDNA concentration and a method for determining ctDNA concentration is disclosed, wherein the method comprising dissolving extracted ctDNA in Tris-HCl buffer with pH>7.0 and adding into the buffer 2,7-bis(1-methyl-4-vinylpyridine)-9-ethylcarbazole iodised salt as a molecular probe, calculating the concentration of ctDNA in the solution by measuring the Fluorescence intensity of the solution. It has extremely high sensitivity in the determination of 0 μg/ml˜50 μg/ml ctDNA solution.

公开(公告)号：US08003792B2

公开(公告)日：2011-08-23

申请号：US11662703

申请日：2005-09-09

申请人： Ian M. Bell ,  Cory R. Theberge ,  Craig A. Stump ,  Xufang Zhang ,  Steven N. Gallicchio ,  C. Blair Zartman

发明人： Ian M. Bell ,  Cory R. Theberge ,  Craig A. Stump ,  Xufang Zhang ,  Steven N. Gallicchio ,  C. Blair Zartman

IPC分类号： A61K31/40 ,  A61K31/438 ,  C07D401/04 ,  C07D227/02

CPC分类号： C07D401/14 ,  C07D403/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D519/00 ,  Y02P20/582

摘要： The present invention is directed to compounds of Formula I: (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

摘要翻译： 本发明涉及式I化合物（其中变量A1，A2，B，J，K，m，n，R4，R5a，R5b和R5c如本文所定义）可用作CGRP受体的拮抗剂，并且可用于 治疗或预防CGRP涉及的疾病，如头痛，偏头痛和丛集性头痛。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的用途。

公开(公告)号：US5688945A

公开(公告)日：1997-11-18

申请号：US770488

申请日：1996-12-20

申请人： Susanna Karin Maria Bjork ,  Birgitta Kristina Gotthammar ,  Mats Torbjorn Linderberg ,  Johan Per Luthman ,  Kerstin Margareta Irma Persson ,  Robert Schwarcz

发明人： Susanna Karin Maria Bjork ,  Birgitta Kristina Gotthammar ,  Mats Torbjorn Linderberg ,  Johan Per Luthman ,  Kerstin Margareta Irma Persson ,  Robert Schwarcz

IPC分类号： C07D333/04 ,  A61K31/195 ,  A61K31/196 ,  A61K31/275 ,  A61K31/34 ,  A61K31/341 ,  A61K31/38 ,  A61K31/381 ,  A61P9/10 ,  A61P25/00 ,  A61P43/00 ,  C07C205/26 ,  C07C205/37 ,  C07C205/59 ,  C07C227/04 ,  C07C227/16 ,  C07C227/18 ,  C07C229/64 ,  C07C229/70 ,  C07C253/30 ,  C07C255/57 ,  C07C255/59 ,  C07C315/04 ,  C07C317/46 ,  C07C317/48 ,  C07C319/20 ,  C07C323/62 ,  C07C323/63 ,  C07D307/34 ,  C07F7/12 ,  C07D227/02 ,  C07C315/00 ,  C07C317/00

CPC分类号： C07C205/59 ,  C07C205/26 ,  C07C205/37 ,  C07C229/64 ,  C07C229/70 ,  C07C255/59 ,  C07C2102/10

摘要： The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R.sup.3, R.sup.4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z--R.sup.5 wherein Z is selected from CH.sub.n, NH.sub.m, O, S, SO.sub.2 and CO wherein n=1 or 2; m=0 or 1 and R.sup.5 is selected from alkyl, aryl and fluoroalkyl; or R.sup.3 and R.sup.4 together form a saturated or unsaturated ring system Y--V--Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C.sub.1 -C.sub.3 alkylene or alkenylene, --N.dbd., --N.dbd.N-- and ##STR2## wherein R.sub.7 =H or alkyl; or a pharmaceutically acceptable salt thereof, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof for inhibiting the enzyme 3-hydroxy-anthranilate oxygenase, 3-HAO, responsible for the production of the endogenous neurotoxin quinolinic acid, QUIN.

摘要翻译： 本发明涉及通式Ⅰ的3-羟基邻氨基苯甲酸的新型衍生物，3-HANA，其中R 1和R 2相同或不同并且选自H和烷基; X选自烷硫基，芳硫基，芳氧基，卤素和氰基; R 3，R 4相同或不同，选自卤素，甲基，氟烷基，氰基和Z-R 5，其中Z选自CH n，NH m，O，S，SO 2和CO，其中n = 1或2; m = 0或1，R 5选自烷基，芳基和氟烷基; 或R3和R4一起形成饱和或不饱和的环系YVZ，其中Y和Z彼此独立地如上述Z所定义，V选自C 1 -C 3亚烷基或亚烯基-N =，-N = N- 和＆lt; IMAGE＆gt;其中R7 = H或烷基; 或其药学上可接受的盐，其制备方法和中间体，新型药物组合物及其用于抑制负责产生内源性神经毒素喹啉酸QUIN的3-羟基 - 邻氨基苯甲酸加氧酶3-HAO的用途。

公开(公告)号：US3936467A

公开(公告)日：1976-02-03

申请号：US454643

申请日：1974-03-25

申请人： Richard William James Carney ,  George DE Stevens

发明人： Richard William James Carney ,  George DE Stevens

IPC分类号： C07D207/20 ,  C07D207/26 ,  C07D207/27 ,  C07D207/40 ,  C07D207/404 ,  C07D207/44 ,  C07D207/448 ,  C07D209/44 ,  C07D209/46 ,  C07D209/48 ,  C07D211/40 ,  C07D217/24 ,  C07D227/02 ,  C07D295/18

CPC分类号： C07D207/27 ,  C07C255/00 ,  C07D207/20 ,  C07D207/404 ,  C07D207/448 ,  C07D209/44 ,  C07D209/46 ,  C07D209/48 ,  C07D217/24 ,  C07D295/18 ,  Y10S514/825

摘要： New .alpha.-(cyclic tert. aminophenyl)-aliphatic acids, e.g. those of the formula ##SPC1##R.sub.1 = h or alkylR.sub.2 = h, alk(en)yl, cycloalk(en)- yl or cycloalk(en)yl-alkylA = hydroxylated lower alkyleneAnd functional derivatives thereof, are anti-inflammatory agents.

摘要翻译： 新的α-（环状叔氨基苯基） - 脂族酸，例如 式R1 = H或烷基R2 = H，烷（烯）基，环烯（en） - 基或环烷基（烯）基 - 烷基A =羟基化低级亚烷基及其功能衍生物，为抗炎剂。

公开(公告)号：US20170305861A1

公开(公告)日：2017-10-26

申请号：US15496631

申请日：2017-04-25

申请人： ImmunoMet Therapeutics, Inc

发明人： Sung Wuk Kim ,  Hong Woo Kim ,  SangHee Yoo ,  Hyunwook Kim ,  Hye Jin Heo ,  Hong Bum Lee ,  Jiae Kook ,  Young Woo Lee

IPC分类号： C07D227/02 ,  A61K45/06 ,  C07C11/02 ,  C07D283/00

CPC分类号： C07D227/02 ,  A61K45/06 ,  A61P35/00 ,  C07C11/02 ,  C07D283/00

摘要： The present invention relates to heteroaryl compounds comprising nitrogen and use thereof, and more specifically to compounds which exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient.The compounds according to the present invention exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer with a reduced dose compared to that of existing drugs. Accordingly, the compounds can be effectively used for treating various types of cancer, such as uterine cancer, breast cancer, gastric cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, and liver cancer, and for inhibiting proliferation of cancer cells and metastasis of cancer.